Well i guess that makes me unwary and an amateur. I am surprised...

Well i guess that makes me unwary and an amateur. I am surprised that everyone is falling for this deramp. Perhaps I should elaborate further. Mesoblast has had an equity facility agreement available with Melbourne based Kentgrove Capital since 2016. Greed is good ...perhaps you can tell us what discount this has been agreed at ? If your struggling for help ...i could tell you...but then again I am an amateur...but i will give you a clue..its considerably less than 5%...but of course it has not been drawndown because the Company most likely feels it has other less dilutive sources of finance available to it ! It has proven this several times in the last year with the Tasly &NovaQuest deals not to mention the Takeda milestones which have taken everyone off guard. Madamswer is touching on a raw nerve because we are all aware that additional funds will have to come from somewhere to complete clinical trials just before revenues from aGVHD ramp up.
The Pharma industry is moving to a different financing model for late stage financing of clinical trials...let me help you again...because i am just an amateur.
Companies like Royalty Pharma are transforming the sector with a sophisticated approach to funding late stage clinical trials.
https://www.royaltypharma.com
These type of deals are far less dilutive to shareholders than a plain vanilla equity raise.
I believe that there are plenty of other hedge funds with alternative investment strategies teams or private equity funds who would give their right arms to get involved with this IP.
I do not believe there will be a fundraise when there are so many obvious alternatives to be pursued. As others have pointed out , there are licencees who are committed to marketing and manufacturing MSC’s in their own territories (eg Japan & China ). These costs would be recovered far more effectively if they extended the number of therapies which are covered under these agreements. Then there is the obvious opportunity to find a European distribution partner for aGVHD , CLBP, etc.,
Then there is the question of why SI has not concluded a global licensing agreement ? I think the answer is simple. Why give away what Is often a standard 55-60% interest now in future revenues from blockbuster products ...when waiting just a few more months for the CHF to complete.... will presumably allow MSB to secure substantially better terms. In the very short term i have no idea where the share price will go...but i do believe that some ulterior motives are behind some recent negative postings. NONE of our negative posters have ever tried to analyse the success of the clinical trial results or objectively look at the sunk costs involved in getting here. Large Pharma, has by and large, ceased funding ambitious clinical pipelines but prefers to engage with independents closer to approval. Incyte secured deals from Innovent and Novartis for aGVHD and I see no reason why Mesoblast should be in any different situation if it wanted to. I believe the next few months will be transformational for the company. Hope your all on board when the fun starts !